Seaside Therapeutics has revealed its second failed study for its lead drug STX209 this month. In one of two Phase III studies for the compound for the genetic mental disorder Fragile X syndrome, STX209 treatment missed its main goal of reducing social withdrawal.
Seaside Therapeutics missed the main target of a midstage trial of its lead drug STX209 in patients with autism spectrum disorder (ASD), yet benefits of treatment observed in the Phase IIb study have driven the company to plan another major clinical trial in patients with the intellectual disorder.
A new mouse model of autism adds to growing evidence that genetics is a strong factor, if not the strongest, driving the neural development disorder.
A lot of the current vitriol aimed at vaccines can be traced back to reports ofautism links in the 1990s. The association has remained lodged in the minds of many even as research has discredited the original paper, and consistently found no link between vaccines and autism.
Asuragen is celebrating encouraging clinical data, suggesting one of its molecular diagnostic tests is better than existing standards of care in determining how likely a woman will have a child with Fragile X syndrome--a genetic cause of autism spectrum disorders and other intellectual disabilities.
SynapDx is allying with gene sequencer Illumina to explore development of diagnostic tools for autism spectrum disorders and other "opportunities in neurodevelopment."
Researchers have yet to crack the code on how to predict whether an individual will develop autism. But Touro College of Osteopathic Medicine scientist Gary Steinman has uncovered a potential connection between autism and a growth protein that may shed some light on the subject.
A team of Canadian and U.S. researchers believe they've come up with a possible blood test option for autism, something that could help spot a unique pattern of fat metabolism blood markers found in a sizeable minority of children with the disorder.
Primarily known for its work on Fragile X, a well-known autism target, Afraxis says that the giant Roche subsidiary will pay up to $187.5 million in milestones and an undisclosed upfront in order to develop the compounds for a "novel target."
Autism spectrum disorders reportedly affect 1 in 88 people in the U.S., but there remain no reliable biomarkers to diagnose them in early stages. That's not for lack of effort, however, and the journal Disease Markers points out that researchers have made some progress in mapping the prevalent affliction.